id: smoking_cessation_treatment_use_to_NEW:adverse_events_smoking_cessation
name: Smoking Cessation Treatment Use â†’ Adverse Events from Smoking Cessation Interventions
from_node:
  node_id: smoking_cessation_treatment_use
  node_name: Smoking Cessation Treatment Use
to_node:
  node_id: NEW:adverse_events_smoking_cessation
  node_name: Adverse Events from Smoking Cessation Interventions
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: Use of smoking cessation treatments (including e-cigarettes) may produce side effects'
- 'Step 2: Nicotine delivery from any source can cause throat/mouth irritation, nausea'
- 'Step 3: Monitoring for adverse events during cessation treatment'
- 'Step 4: Low-certainty evidence suggests increased AEs with nicotine EC vs behavioral support alone'
evidence:
  quality_rating: A
  n_studies: 49
  primary_citation: Nicola Lindson et al. 2025. "Electronic cigarettes for smoking cessation.." https://doi.org/10.1002/14651858.CD010216.pub9
  supporting_citations:
  - Safety data from included RCTs in systematic review
  - Comparison of adverse event rates across intervention arms
  - Additional citations require full-text access
  doi: 10.1002/14651858.CD010216.pub9
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: Overall incidence of serious adverse events was low across all study arms. No evidence of
  serious harm from nicotine e-cigarettes was detected, though confidence intervals were wide. Longer
  and larger studies needed to fully evaluate safety.
quantitative_effects:
  sample_size: 29044
moderators:
- name: comparison_group
  direction: u_shaped
  strength: weak
  description: No difference in AEs between nicotine and non-nicotine ECs or between nicotine ECs and
    NRT; low-certainty evidence for increased AEs vs behavioral support only
- name: product_type
  direction: strengthens
  strength: moderate
  description: Illicit products and those containing THC may have different harm profiles than regulated
    nicotine EC
structural_competency:
  equity_implications: Product safety is determined by regulatory frameworks, quality control standards,
    and market oversight. Unregulated markets may expose users to greater risks. Structural factors include
    FDA regulation, state-level policies, and enforcement capacity. Equity implications involve differential
    access to regulated versus illicit products based on cost and availability.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:36.907549'
  extraction_confidence: medium
  prompt_version: 2.1-canonical-validated
